Community Practice Connections™: Comprehensive Key Advances in Biosimilars for Retinal Diseases – Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Specialist
Released On
October 12, 2022
Expires On
October 12, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Ophthalmology
Topic(s)
Eye Disorders
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Biogen, Inc.
Credit Available
- Optometrists — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is directed toward retinal and general ophthalmologists and other health care professionals involved in the treatment of patients with retinal diseases, such as optometrists, advanced practitioners, and nurses.
Program Overview
Regular intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors are a standard of care for retinal diseases such as neovascular age-related macular degeneration and diabetic retinopathy. However, frequent injections of these biologic therapies create an economic burden for the health care system and patients. Like in other specialties such as oncology and rheumatology, recent developments in biosimilars have the potential to reduce costs in the ophthalmology space.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a live satellite symposium presented at the ASRS Annual Meeting 2022, held in July. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of using biosimilars for managing retinal diseases, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives
- Upon completion of this activity, participants should be better able to:
-
- Review the regulatory requirements for agents that are approved as biosimilars for reference biologic agents
- Evaluate clinical evidence for biosimilars compared with reference biologic agents as treatment for retinal diseases
- Develop strategies to address concerns regarding the use of biosimilars in patients with retinal diseases
Faculty
Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Johns Hopkins Medicine
Baltimore, MD
Jennifer I. Lim, MD, FARVO
Professor of Ophthalmology
Marion H. Schenk Esq., Chair in Ophthalmology for Research in the Aging Eye
Vice Chair for Diversity and Inclusion
Director, Retina Service
University of Illinois at Chicago
Chicago, IL
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Physicians’ Education Resource®, LLC, (PER) is accredited by COPE to provide continuing education to optometrists.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Neil M. Bressler, MD
-
- Grant/Research Support: Bayer, Biogen, Regeneron, Roche, Samsung Bioepis
- Jennifer I. Lim, MD, FARVO
-
- Grant/Research Support: Genentech/Roche, Regeneron, Stealth BioTherapeutics, NGM Biopharmaceuticals, Chengdu Kanghong, Aldeyra, Graybug
- Consultant: Aura Biosciences, Luxa Biotechnology, Quark Pharmaceuticals, Santen, Opthea, Novartis, Iveric, Eyenuk, Unity Biotechnology, Viridian, Cognition Therapeutics, Adverum
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
-
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
- You may immediately download your certificate.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and aboveSupported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or aboveOff-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.